Securities offered through B.A Securities. Member FINRA/SIPC
DescriptionClearlight Diagnostics is developing a next generation, integrated instrumentation platform for tumor tissue processing and 3-D imaging, focused on immuno oncology clinical applications. These technologies were developed by Karl Deisseroth, M.D., Ph.D., and his colleagues at Stanford University and have been utilized extensively to understand high content neuronal mapping and phenotyping of the mouse brain at resolutions and imaging speeds that are unprecedented. ClearLight has licensed exclusive rights to the technology from Dr. Deisseroth’s lab at Stanford University and holds a solid IP portfolio including technology, assay, and imaging patent applications.
- Pursuing Series C financing
- USD $6M raised to date
- Licensed novel tissue processing and 3D imaging that will be applied to the Oncology Markets
- Developing a next generation automated tissue processing and imaging instrument and reagent platform for research and diagnostic applications in Oncology
- Looking to move to commercialization